Modeling and Simulation - PK/PD Archives | Page 9 of 39 | Certara

Publication

Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110

CertaraJanuary 17, 2020

On-Demand Webinar

How to Perform IVIVC for Delayed Release Drug Formulations

This webinar showed how to use a time correction factor to establish a meaningful IVIVC…

CertaraAugust 20, 2019

Poster

Population Pharmacokinetics of Piperacillin-Tazobactam Extended Infusions in Paediatric Population

CertaraJune 24, 2019

Poster

Pharmacodynamics of rituximab on B cells in paediatric post-HSCT patients with EBV

CertaraJune 24, 2019

White Paper

Optimize Immuno-oncology Drug Discovery and Development Using QSP

A Quantitative Systems Pharmacology (QSP) approach for developing combination immune-oncology therapies can be used to…

CertaraJune 19, 2019

Brochure

Pirana Modeling Workbench

Pirana is a flexible and extendible modeling workbench with an intuitive graphical user interface for…

CertaraMay 28, 2019

Poster

Population Pharmacokinetic Analysis of DS-8201a, A HER2-Targeting Antibody-Drug Conjugate, in Patients with HER2-Positive Breast Cancer or Other Solid Tumors

CertaraMay 2, 2019

Poster

Simulating the Impact of the Interplay Between CYP2C19 Polymorphisms and Ethnicity on Response to Clopidogrel, Using PBPK-PD Models

CertaraApril 22, 2019

Poster

Exposure-Response Analyses to Support Dose Justification of DS-8201A, A HER2-Targeting Antibody-Drug Conjugate, in HER2-Positive Breast Cancer Patients

CertaraApril 22, 2019

Poster

Relationship of Ivosidenib Plasma Concentration to Heart Rate-Corrected QT Interval in Patients with IDH1-Mutant Advanced Hematologic Malignancies

CertaraApril 22, 2019

© 2025 Certara. All Rights Reserved. | Privacy policy